VRNA Verona Pharma
- 14.850
- +0.100+0.68%
- 14.850
- 0.0000.00%
Verona Pharma News
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
Verona Pharma Plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
Verona Pharma | 10-Q: Quarterly report
Verona Pharma Gets $650M in Financing Ahead of June FDA Decision on COPD Asset
Verona Pharma Shares Decline After Q1 Loss Widens
Verona Pharma's (VRNA) shares were down 0.2% in recent Thursday trading after the company reported a Q1 net loss of $0.04 per diluted share, compared with a loss of $0.03 a year earlier. Analysts surv
Verona Pharma Plc Secures Funding and Negotiates Sales Milestones
Express News | Verona Pharma Q1 2024 GAAP EPS $(0.04) Beats $(0.22) Estimate
Express News | Verona Pharma Announces $650M Strategic Financing With Oaktree and OMERS, Cash Runway Extended Beyond 2026
Verona Pharma Cash and Cash Equivalents at March 31 Were $254.9M >VRNA
Verona Pharma Cash and Cash Equivalents at March 31 Were $254.9M >VRNA
Verona Pharma Believes Cash and Cash Equivalents Will Fund Planned Operating Expenses and Cap Expenditure Requirements Beyond 2026 >VRNA
Verona Pharma Believes Cash and Cash Equivalents Will Fund Planned Operating Expenses and Cap Expenditure Requirements Beyond 2026 >VRNA
Press Release: Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong
Verona Pharma 1Q Loss $25.8M >VRNA
Verona Pharma 1Q Loss $25.8M >VRNA
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activitiesCash runway extended beyond 2026LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDUFA Target Action Date for Ensifentrine of June 26, 2024Finalizing commercial launch preparationsStrong balance sheet supports commercialization and pipeline expansionConference call today at 9:00 a
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower
European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde
Express News | Verona Pharma To Present Additional Analyses Of Phase 3 ENHANCE Studies In COPD At ATS 2024
When Will Verona Pharma Plc (NASDAQ:VRNA) Breakeven?
We feel now is a pretty good time to analyse Verona Pharma plc's (NASDAQ:VRNA) business as it appears the company may be on the cusp of a considerable accomplishment. Verona Pharma plc, a clinical s
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31,
Express News | Verona Pharma PLC : Btig Raises Target Price to $34 From $31
Analysis
Price Target
No Data
